Fibroblast growth factor-23 and cardiovascular disease among prevalent hemodialysis patients focusing on residual kidney function

Background In patients undergoing incident hemodialysis, increased fibroblast growth factor-23 (FGF-23) levels are associated with the development of cardiovascular disease (CVD), but influence residual kidney function (RFK) on this association is unclear. This study aimed to investigate between FGF-23 levels, RKF, and CVD in prevalent hemodialysis. Methods cross-sectional longitudinal observational included 296 maintenance hemodialysis for at least three months who were followed up a median 44 months. RKF was defined as 24-h urine output >200 mL, left ventricular (LV) diastolic dysfunction E/E’ >15 echocardiographic parameters. hospitalization or emergency room visits due causes, such angina, myocardial infarction, congestive heart failure. Results The intact (iFGF-23) level 423.8 pg/mL (interquartile range, 171–1,443). Patients an > significantly had lower proportion (39.2% vs. 60.1%, P < 0.001) higher LV (54. 1% 29.1%, than those iFGF-23 ≤ pg/mL. odds ratio (OR) RFK (OR per one-unit increase natural log-transformed 1.80; 95% confidence interval [CI]: 1.11–2.93) without levels: 1.42; CI: 1.01–1.99) multivariate analysis (p 0.001). During follow-up period, 55 experienced CVD. hazard (HR) also (HR 2.64; 1.29–5.40) 1.44; 1.04–1.99) = 0.05). Conclusions Increased hemodialysis; however, loss attenuated magnitude these associations. Therefore, patients, strongly influenced detrimental role